Following the COVID-19 pandemic, mRNA-based vaccines have been shown to provide rapid and precise immune responses, however, this technology has much wider applications.
At the Royal College of Physicians on Thursday 27th July, Sanofi held an event focused on the state of UK life sciences and what can be done at this critical moment in time.
Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS on the grounds that it is not cost-effective.